Investigational drug · Phase 2
HRS-9563
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Mild to Moderate Hypertension.
Phase 2Last checked: Nov 20, 2026Latest source record: Jul 31, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "HRS-9563"
First trial start
2026
Jan 14, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "HRS-9563", any sponsor or status.
Conditions studied
As listed on its trial records.
- Mild to Moderate Hypertension
Approved drugs for the same conditions: High blood pressure (hypertension) · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "HRS-9563" as an intervention, largest first.
- Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate HypertensionPivotal-lookingActive, not recruiting
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07297797 · 238 participants · Start Jan 14, 2026 · Primary completion Dec 2026
Drug: HRS-9563 Injection; sodium chloride injection · For: Mild to Moderate Hypertension
Sites: Beijing, China
Fujian Shengdi Pharmaceutical Co., Ltd.Industry
NCT07117474 · 60 participants · Start Dec 24, 2024 · Primary completion Jun 9, 2026
Drug: HRS-9563, placebo · For: Subjects With Mild Hypertension
Sites: Hangzhou, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Mild to Moderate Hypertension
- ZilebesiranALN-AGT01Phase 34 trials
Alnylam Pharmaceuticals · Hypertension, High Cardiovascular Risk, High Risk Cardiovascular Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.